Allogeneic stem cell transplantation following reduced-intensity conditioning can induce durable clinical and molecular remissions in relapsed lymphomas: pre-transplant disease status and histotype heavily influence outcome

The safety and efficacy of reduced-intensity conditioning (RIC)followed by allogeneic stem cell transplantation (SCT) for relapsed lymphomas remains unresolved. We conducted a prospective, multicentered, phase II trial. A total of 170 relapsed/refractory lymphomas received a RIC regimen followed by SCT from sibling donors. The primary study end point was non-relapse mortality (NRM). Histologies were non-Hodgkin\u2019s lymphomas (NHL) (indolent (LG-NHL), n=63; aggressive (HG-NHL), n=61; mantle cell lymphoma (MCL),n=14) and Hodgkin\u2019s disease (HD, n=32). Median follow-upwas 33 months (range, 12\u201382). The results show that frequencieswere as follows: cumulative NRM at 3 years, 14%; acuteand chronic graft-versus-host disease (GVHD) 35 and 52%,respectively; 3-year overall survival (OS), 69% for LG-NHL, 69%for HG-NHL, 45% for MCL and 32% for HD (P=0.058); and 3-yearrelapse incidence, 29, 31, 35 and 81%, respectively (P